A citation-based method for searching scientific literature

Zimin Pan, Xing Xie. Oncotarget 2017
Times Cited: 13







List of co-cited articles
43 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
30

Structure-Function Of The Tumor Suppressor BRCA1.
Serena L Clark, Ana M Rodriguez, Russell R Snyder, Gary D V Hankins, Darren Boehning. Comput Struct Biotechnol J 2012
80
23

PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Fan Zhang, Qiang Fan, Keqin Ren, Paul R Andreassen. Mol Cancer Res 2009
190
23

BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.
Inês Godet, Daniele M Gilkes. Integr Cancer Sci Ther 2017
57
23

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
23


Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray. Int J Cancer 2015
15

Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.
Junran Zhang, Henning Willers, Zhihui Feng, Jagadish C Ghosh, Sang Kim, David T Weaver, Jay H Chung, Simon N Powell, Fen Xia. Mol Cell Biol 2004
230
15

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Xi-Chun Hu, Jian Zhang, Bing-He Xu, Li Cai, Joseph Ragaz, Zhong-Hua Wang, Bi-Yun Wang, Yue-E Teng, Zhong-Sheng Tong, Yue-Yin Pan,[...]. Lancet Oncol 2015
142
15

BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.
Ronit I Yarden, Sherly Pardo-Reoyo, Magda Sgagias, Kenneth H Cowan, Lawrence C Brody. Nat Genet 2002
365
15


Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
15

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
667
15

BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
S S Yuan, S Y Lee, G Chen, M Song, G E Tomlinson, E Y Lee. Cancer Res 1999
329
15



Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
15

Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.
R S Tibbetts, D Cortez, K M Brumbaugh, R Scully, D Livingston, S J Elledge, R T Abraham. Genes Dev 2000
389
15

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
665
15

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
402
15

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.
Angela Toss, Chiara Tomasello, Elisabetta Razzaboni, Giannina Contu, Giovanni Grandi, Angelo Cagnacci, Russell J Schilder, Laura Cortesi. Biomed Res Int 2015
82
15

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
468
15

The biology of ovarian cancer: new opportunities for translation.
Robert C Bast, Bryan Hennessy, Gordon B Mills. Nat Rev Cancer 2009
936
15

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
15

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
Sanghamitra Mylavarapu, Asmita Das, Monideepa Roy. Front Oncol 2018
54
15


Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
Claudia Allemani, Hannah K Weir, Helena Carreira, Rhea Harewood, Devon Spika, Xiao-Si Wang, Finian Bannon, Jane V Ahn, Christopher J Johnson, Audrey Bonaventure,[...]. Lancet 2015
15

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
719
15

Mechanism of eukaryotic homologous recombination.
Joseph San Filippo, Patrick Sung, Hannah Klein. Annu Rev Biochem 2008
15

PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Shirley M H Sy, Michael S Y Huen, Junjie Chen. Proc Natl Acad Sci U S A 2009
350
15

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
509
15



PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Feng Zhang, Jianglin Ma, Jiaxue Wu, Lin Ye, Hong Cai, Bing Xia, Xiaochun Yu. Curr Biol 2009
336
15

Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection.
Ruth M Densham, Alexander J Garvin, Helen R Stone, Joanna Strachan, Robert A Baldock, Manuel Daza-Martin, Alice Fletcher, Sarah Blair-Reid, James Beesley, Balraj Johal,[...]. Nat Struct Mol Biol 2016
141
15

Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
Jing Zhuang, Junran Zhang, Henning Willers, Hong Wang, Jay H Chung, Dik C van Gent, Dennis E Hallahan, Simon N Powell, Fen Xia. Cancer Res 2006
85
15

Cancer statistics, 2016.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2016
15

The forefront of ovarian cancer therapy: update on PARP inhibitors.
M R Mirza, R L Coleman, A González-Martín, K N Moore, N Colombo, I Ray-Coquard, S Pignata. Ann Oncol 2020
53
15

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
42
15

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
853
15

Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Kristen E Mengwasser, Richard O Adeyemi, Yumei Leng, Mei Yuk Choi, Connor Clairmont, Alan D D'Andrea, Stephen J Elledge. Mol Cell 2019
70
15

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
15

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
15

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
340
7

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
660
7

High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Seung Jin Kim, Yasuo Miyoshi, Tetsuya Taguchi, Yasuhiro Tamaki, Hajime Nakamura, Junji Yodoi, Kikuya Kato, Shinzaburo Noguchi. Clin Cancer Res 2005
139
7

Linkage of early-onset familial breast cancer to chromosome 17q21.
J M Hall, M K Lee, B Newman, J E Morrow, L A Anderson, B Huey, M C King. Science 1990
7

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.
D E Jensen, M Proctor, S T Marquis, H P Gardner, S I Ha, L A Chodosh, A M Ishov, N Tommerup, H Vissing, Y Sekido,[...]. Oncogene 1998
496
7


Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer.
Fleur Huang, Yael B Kushner, Adrian Langleben, William D Foulkes. Nat Rev Clin Oncol 2009
15
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.